Overview

A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2007-10-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the tolerability, pharmacokinetics and antitumor effect of bendamustine hydrochloride (SyB L-0501) in patients with indolent B-cell Non-Hodgkin's Lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
SymBio Pharmaceuticals
Treatments:
Bendamustine Hydrochloride